Thibodaux Regional Health System continues to adopt leading edge COVID-19
treatment options, and is actively participating in innovative clinical
research and treatment advancements with Mayo Clinic and GE.
Thibodaux Regional is the first hospital in the region to begin using blood
plasma therapy as a treatment for COVID-19. This treatment is being performed
as part of a clinical trial with Mayo Clinic.
Plasma donated by someone who has recovered from COVID-19 may be helpful
in treating a person hospitalized with a severe or life-threatening case.
Plasma contains antibodies that can immediately affect a person’s
immunity, and potentially lessen the severity or shorten the length of
Plasma donated from one individual can be used to treat up to four patients.
Individuals who have had COVID-19 and have recovered can call 985.435.4813
for information on how to become a donor.
In addition, Thibodaux Regional has entered into an agreement with GE Healthcare
to participate in a study that will utilize data analytics to develop
Artificial Intelligence (AI) that would assist in future screening, detection,
triage and monitoring of COVID-19 cases. GE will use de-identified data
from Cat (CT) Scan and X-ray imaging from COVID-19 and pneumonia patients
to create an algorithm that would aid in developing the AI Imaging models.
“Thibodaux Regional is proud to partner with world-renowned organizations
such as Mayo Clinic and GE to provide leading edge treatment options for
Covid-19 patients,” said Greg Stock, CEO Thibodaux Regional. “These
new advancements in clinical care appear promising. We remain committed
to bringing progressive treatment options to our region.”
# # #